Several studies reported that SMYD2 is overexpressed in the tumor cells lines and patients’ tissues of some cancer types, including esophageal squamous cell carcinoma and acute lymphoblastic leukemia, which suggests SMYD2 as a potential drug target in these cancers [9, 12, 13]. Here, SMYD2 is linked to neoplasm.